Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE – primary prevention study
Author:
Kim G. Smolderen,Carlos Mena-Hurtado,Victoria Divino,Zhenxiang Zhao,Yan Chen,Joanna Boland,Ariel Chao,Jinlin Song,B. Gabriel Smolarz,Filip K. Knop,Michael G. Nanna
Publication:
American Journal of Preventive Cardiology
© 2026 The Authors. Published by Elsevier B.V.